1
James Aggen, John H Griffin, Mathai Mammen, Daniel Marquess, Edmund J Moran, David Oare: Muscarinic receptor antagonists. Theravance, Jeffrey A Hagenah, Joyce G Cohen, February 17, 2004: US06693202 (123 worldwide citation)

Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modu ...


2
Mathai Mammen, David Oare: Therapeutic ureas. Theravance, Jeffrey A Hagenah, David E Boone, October 21, 2003: US06635764 (76 worldwide citation)

This invention relates to urea compounds that are muscarinic receptor antagonists and agonists, pharmaceutical compositions comprising such compounds, and methods of preparing these compounds.


3
James C Marsters Jr, Michael S Brown, Craig W Crowley, Joseph L Goldstein, Guy L James, Robert S McDowell, David Oare, Thomas E Rawson, Mark Reynolds, Todd C Somers: Ras farnesyl transferase inhibitors. Genentech, Board of Regents The University of Texas System, Daryl B Winter, July 2, 1996: US05532359 (54 worldwide citation)

Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated. Also disclosed ar ...


4
David G Lowe, Brian C Cunningham, David Oare, Robert S McDowell, John P Burnier: Receptor specific atrial natriuretic peptides. Genentech, Jeffrey S Kubinec, December 8, 1998: US05846932 (28 worldwide citation)

Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorel ...


5

6
Daniel J Burdick, Mark S Stanley, David Oare, Mark E Reynolds, Thomas R Gadek, James C Marsters: LFA-1 antagonist compounds. Genentech, David W Evans, March 29, 2005: US06872735 (22 worldwide citation)

The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammat ...


7
David Lowe, Brian C Cunningham, David Oare, Robert S McDowell, John Burnier: Receptor specific atrial natriuretic peptides. Genentech, Jeffrey S Kubinec, September 9, 1997: US05665704 (21 worldwide citation)

Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorel ...


8
James C Marsters Jr, Michael S Brown, Craig W Crowley, Joseph L Goldstein, Guy L James, Robert S McDowell, David Oare, Thomas E Rawson, Mark Reynolds, Todd C Somers: Ras farnesyl transferase inhibitors. Genentech, Board of Regents University of Texas, Daryl B Winter, December 1, 1998: US05843941 (17 worldwide citation)

Benzodiazepine derivatives represented by the structure below are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases foe which inhibition of the ras farnesyl:protein transfer ...


9
Mathai Mammen, David Oare: Therapeutic carbamates. Theravance, Jeffrey A Hagenah, Shelley Eberle, July 3, 2007: US07238709 (15 worldwide citation)

This invention relates to hindered carbamate derivatives that are muscarinic receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of preparing these compounds.


10
David G Lowe, Brian C Cunningham, David Oare, Robert S McDowell, John P Burnier: Receptor specific atrial natriuretic peptides. Genentech, Merchant & Gould P C, February 25, 2003: US06525022 (7 worldwide citation)

Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorel ...



Click the thumbnails below to visualize the patent trend.